HPV primary screening algorithm with the cobas® HPV Test identifies more high grade disease than a Pap test alone and maintains screening efficiency
This algorithm leverages the high sensitivity of HPV DNA, the built-in risk stratification of HPV 16/18 genotyping and triage with the high specificity of cytology for an optimal balance in cervical cancer screening.
3-year cumulative incidence rate (CIR) of ≥CIN3 of Pap negative vs HPV DNA negative
A negative cobas® HPV Test provides more than twice the confidence that ≥CIN3 will not develop within 3 years vs cytology alone
The ATHENA study, the largest US prospective registrational clinical study of its kind, evaluated the performance of the HPV Primary Screening Algorithm with the cobas® HPV Test in women ages 25+.
3-year cumulative incidence rate (CIR) of ≥CIN3 by high-risk HPV status
HPV 16 and 18 genotyping allows women to be stratified into distinct groups and managed according to risk
≥CIN3 by age group
28% of ≥CIN3 disease was found in women 25-29 years old
ATHENA data indicates that screening women starting at 25 years with the cobas® HPV Test will help reduce the incidence of high-grade cervical disease
Proportion of women with normal cytology (NILM) diagnosed with ≥CIN3 by age group
Cytology missed >57% of ≥CIN3 in women ages 25-29 confirming the poor performance of cytology alone in younger women